These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21824074)

  • 21. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction.
    Shikuma CM; Day LJ; Gerschenson M
    Curr Drug Targets Infect Disord; 2005 Sep; 5(3):255-62. PubMed ID: 16181144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand.
    Lee B; Aurpibul L; Sirisanthana V; Mangklabruks A; Sirisanthana T; Puthanakit T
    HIV Med; 2009 Feb; 10(2):72-8. PubMed ID: 19018877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.
    Gutierrez AD; Balasubramanyam A
    Endocrine; 2012 Feb; 41(1):1-10. PubMed ID: 22134974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of insulin resistance in a cohort of HIV-infected youth.
    Rosso R; Parodi A; d'Annunzio G; Ginocchio F; Nicolini L; Torrisi C; Sormani MP; Lorini R; Viscoli C; Vignolo M
    Eur J Endocrinol; 2007 Nov; 157(5):655-9. PubMed ID: 17984246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardiovascular risk factors associated with antiretroviral therapy].
    Pérez-Camacho I; Camacho A; Torre-Cisneros J; Rivero A
    Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():24-32. PubMed ID: 20172412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diabetes, insulin resistance and HIV].
    Vallejo O
    Sidahora; 2004; (1):22-5. PubMed ID: 15551439
    [No Abstract]   [Full Text] [Related]  

  • 28. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.
    Walli R; Herfort O; Michl GM; Demant T; Jäger H; Dieterle C; Bogner JR; Landgraf R; Goebel FD
    AIDS; 1998 Oct; 12(15):F167-73. PubMed ID: 9814858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycaemic profile changes by highly active antiretroviral therapy in human immunodeficiency virus-infected patients.
    Duro M; Rebelo I; Barreira S; Sarmento-Castro R; Medeiros R; Almeida C
    Int J STD AIDS; 2015 Oct; 26(11):796-802. PubMed ID: 25281540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disorders of glucose metabolism in the context of human immunodeficiency virus infection.
    Larson R; Capili B; Eckert-Norton M; Colagreco JP; Anastasi JK
    J Am Acad Nurse Pract; 2006 Mar; 18(3):92-103. PubMed ID: 16499742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment.
    Lagathu C; Béréziat V; Gorwood J; Fellahi S; Bastard JP; Vigouroux C; Boccara F; Capeau J
    Expert Opin Drug Saf; 2019 Sep; 18(9):829-840. PubMed ID: 31304808
    [No Abstract]   [Full Text] [Related]  

  • 33. [Metabolic changes in HIV infected patient].
    Castelo Filho A; Abrão P
    Arq Bras Endocrinol Metabol; 2007 Feb; 51(1):5-7. PubMed ID: 17435849
    [No Abstract]   [Full Text] [Related]  

  • 34. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
    Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
    PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin Resistance and the cardiometabolic syndrome in HIV infection.
    Bevilacqua M; Dominguez LJ; Barbagallo M
    J Cardiometab Syndr; 2009; 4(1):40-3. PubMed ID: 19245515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection.
    Howard AA; Lo Y; Floris-Moore M; Klein RS; Fleischer N; Schoenbaum EE
    AIDS; 2007 Mar; 21(5):633-41. PubMed ID: 17314526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy.
    Dejkhamron P; Unachak K; Aurpibul L; Sirisanthana V
    J Pediatr Endocrinol Metab; 2014 May; 27(5-6):403-12. PubMed ID: 24259240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection.
    Samaras K
    J Antimicrob Chemother; 2008 Feb; 61(2):238-45. PubMed ID: 18070830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.
    Naggie S; Hicks C
    J Antimicrob Chemother; 2010 Jun; 65(6):1094-9. PubMed ID: 20418273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.